Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$152M |
| 2 |
AT&T
T
|
+$119M |
| 3 |
Norfolk Southern
NSC
|
+$117M |
| 4 |
CSX Corp
CSX
|
+$115M |
| 5 |
Booking.com
BKNG
|
+$104M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$156M |
| 3 |
C.H. Robinson
CHRW
|
+$134M |
| 4 |
PARA
Paramount Global Class B
PARA
|
+$130M |
| 5 |
BCR
CR Bard Inc.
BCR
|
+$100M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 18.4% |
| 2 | Industrials | 9.75% |
| 3 | Financials | 7.9% |
| 4 | Consumer Staples | 7.89% |
| 5 | Healthcare | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SYKE
1101
DELISTED
SYKES Enterprises Inc
SYKE
| $219K | ﹤0.01% |
+7,252
| New | +$212K |
|
|
AVP
1102
DELISTED
Avon Products, Inc.
AVP
| $219K | ﹤0.01% |
+45,630
| New | +$163K |
|
|
PERY
1103
DELISTED
Perry Ellis International Inc
PERY
| $219K | ﹤0.01% |
11,900
| – | – |
|
|
SCTY
1104
DELISTED
SolarCity Corporation
SCTY
| $219K | ﹤0.01% |
+8,930
| New | +$255K |
|
1105
UGI
UGI
$8.19B
| $218K | ﹤0.01% |
5,400
-6,346
| -54% | -$230K |
|
|
FFG
1106
DELISTED
FBL Financial Group
FFG
| $218K | ﹤0.01% |
+3,540
| New | +$208K |
|
|
WDR
1107
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $217K | ﹤0.01% |
+9,200
| New | +$223K |
|
1108
HUB Group
HUBG
$2.46B
| $215K | ﹤0.01% |
+10,540
| New | +$183K |
|
1109
HealthStream
HSTM
$842M
| $214K | ﹤0.01% |
+9,680
| New | +$199K |
|
1110
Vanda Pharmaceuticals
VNDA
$322M
| $214K | ﹤0.01% |
25,600
-12,860
| -33% | -$106K |
|
1111
Commercial Metals
CMC
$7.18B
| $210K | ﹤0.01% |
12,360
-40,075
| -76% | -$587K |
|
1112
Phibro Animal Health
PAHC
$1.43B
| $210K | ﹤0.01% |
+7,770
| New | +$223K |
|
1113
Thor Industries
THO
$4.13B
| $210K | ﹤0.01% |
3,300
-5,923
| -64% | -$324K |
|
|
PDLI
1114
DELISTED
PDL BioPharma, Inc.
PDLI
| $210K | ﹤0.01% |
63,112
+29,590
| +88% | +$92.2K |
|
|
ABCW
1115
DELISTED
ANCHOR BANCORP WISCONSIN INC COMMON STOCK
ABCW
| $210K | ﹤0.01% |
+4,650
| New | +$198K |
|
|
ACRE
1116
Ares Commercial Real Estate
ACRE
$262M
| $209K | ﹤0.01% |
+19,087
| New | +$199K |
|
1117
Patrick Industries
PATK
$2.73B
| $209K | ﹤0.01% |
+10,373
| New | +$181K |
|
1118
SLM Corp
SLM
$4.95B
| $209K | ﹤0.01% |
32,900
-1,444,812
| -98% | -$8.73M |
|
1119
Foster
FSTR
$394M
| $207K | ﹤0.01% |
11,390
-10,950
| -49% | -$146K |
|
1120
FreightCar America
RAIL
$234M
| $207K | ﹤0.01% |
13,260
-5,640
| -30% | -$97.4K |
|
|
SGYP
1121
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $206K | ﹤0.01% |
74,640
-35,730
| -32% | -$129K |
|
1122
John B. Sanfilippo & Son
JBSS
$882M
| $205K | ﹤0.01% |
2,970
-7,110
| -71% | -$444K |
|
1123
Old Republic International
ORI
$10.1B
| $205K | ﹤0.01% |
11,190
+150
| +1% | +$2.7K |
|
1124
Sanmina
SANM
$9.94B
| $205K | ﹤0.01% |
+8,760
| New | +$176K |
|
1125
Jefferies Financial Group
JEF
$12B
| $204K | ﹤0.01% |
+14,120
| New | +$199K |
|
Similar funds
Dmitry Balyasny's Q1 2016 Portfolio in Review
As of Q1 2016, Dmitry Balyasny held 1,764 positions worth $16.8B, up 17% from $14.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Dmitry Balyasny deployed $2.2B of net new capital in Q1 2016, opening 564 new positions and adding to 341 existing holdings. Its largest new stake was Norfolk Southern: 1,546,641 shares worth $129M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $187M trimmed.
- Dmitry Balyasny's largest Q1 2016 buy was Norfolk Southern: 1,546,641 shares worth $129M.
- Dmitry Balyasny added most to Marathon Petroleum in Q1 2016, an estimated $152M increase.
- Dmitry Balyasny's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $187M.
- Dmitry Balyasny fully exited Union Pacific in Q1 2016, selling an estimated $79.7M.
- Dmitry Balyasny's ten largest holdings make up 12% of its $16.8B portfolio in Q1 2016.
- Dmitry Balyasny opened 564 new positions and closed 526 in Q1 2016.
- Dmitry Balyasny's portfolio value rose 17% quarter-over-quarter to $16.8B.
Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.